Montreux Equity Partners

Imperative Care, Inc. is a medical technology company based in Campbell, California, established in 2015. The company specializes in developing innovative solutions aimed at enhancing the diagnosis, treatment, and rehabilitation of stroke patients. Its primary offerings include the Large Distal Platform, a catheter designed to facilitate access to treatment sites for both ischemic and hemorrhagic stroke procedures, and the ZOOM Aspiration System, which works in conjunction with the Large Distal Platform to provide a comprehensive solution for clot removal across various occlusion sizes. By focusing on improving the speed and effectiveness of acute stroke treatment, Imperative Care aims to address significant unmet needs in stroke care, ultimately providing patients with better prospects for recovery.

Tebra Technologies is a provider of digital tools and support designed to assist independent healthcare practices in navigating the complexities of the modern healthcare landscape. The company has developed a comprehensive medical technology platform that enables these practices to enhance patient acquisition, streamline care management through a fully certified electronic health record system, and improve patient engagement and billing processes. By consolidating essential functions into a single, efficient system, Tebra aims to empower healthcare professionals to optimize their operations and achieve greater success in a fragmented industry.

KEO World is a FinTech company based in Miami, Florida, that specializes in all-digital inventory financing and B2B payment solutions. The company aims to facilitate business growth for both buyers and suppliers by providing innovative financial services across the U.S., Mexico, and Latin America through its Global Trade program. KEO World leverages artificial intelligence and machine learning to analyze banking transactional data, allowing it to offer loans and instant funding to businesses and consumers quickly and efficiently. By streamlining the financing process, KEO World enhances access to capital, ultimately supporting the financial needs of its clients in a rapidly evolving market.

FinPay Holdings, LLC, established in 2015 and headquartered in King of Prussia, Pennsylvania, specializes in developing software for patient financial management. Its platform enables patients to manage their healthcare finances through various payment options, automated programs, consumer loans, and installment plans. FinPay aims to address the affordability crisis in healthcare by improving the patient financial experience, expanding financial literacy, advocating for cost transparency, and offering affordable payment solutions. This empowers healthcare providers with analytic insights to manage financial risks and maximize patient payments.

FinPay Holdings, LLC, established in 2015 and headquartered in King of Prussia, Pennsylvania, specializes in developing software for patient financial management. Its platform enables patients to manage their healthcare finances through various payment options, automated programs, consumer loans, and installment plans. FinPay aims to address the affordability crisis in healthcare by improving the patient financial experience, expanding financial literacy, advocating for cost transparency, and offering affordable payment solutions. This empowers healthcare providers with analytic insights to manage financial risks and maximize patient payments.

TigerConnect is a provider of clinical communication solutions tailored for the healthcare sector, enabling effective collaboration among doctors, nurses, patients, and care providers. Founded in 2010 and headquartered in Santa Monica, California, the company offers a platform that integrates real-time mobile messaging with a user-friendly interface, while prioritizing security and privacy. Trusted by over 4,000 healthcare organizations, TigerConnect processes more than 10 million messages daily and boasts a 99.99% uptime. Its innovative products and seamless integrations with essential hospital systems enhance workflow efficiency, ultimately accelerating productivity, reducing costs, and improving patient outcomes. The company's commitment to client success is evident through its dedicated support organization, which collaborates with clients to optimize communication workflows and maximize return on investment.

Pulmonx Corporation is a medical technology company specializing in minimally invasive solutions for the diagnosis and treatment of chronic obstructive pulmonary disease (COPD), particularly severe emphysema. Its primary offerings include the Zephyr Endobronchial Valve, designed for patients with hyperinflation due to emphysema, as well as the Chartis Pulmonary Assessment System, which assesses collateral ventilation, and the StratX Lung Analysis Platform, a cloud-based service that analyzes computed tomography data to identify suitable treatment areas. Pulmonx aims to improve the quality of life for patients who remain symptomatic despite medical management and may not be candidates for surgical interventions. The company has received FDA pre-market approval for the Zephyr Valve and has established a global presence, serving markets in the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. Founded in 1995 and headquartered in Redwood City, California, Pulmonx has become a leader in interventional procedures for COPD, supported by extensive clinical evidence demonstrating the effectiveness of its technologies.

Crown Laboratories, Inc. is a specialty pharmaceutical company based in Johnson City, Tennessee, founded in 2000. The company focuses on producing both prescription and non-prescription drugs, as well as cosmetic products aimed at enhancing skin health. Its product portfolio includes a range of aesthetic solutions such as SkinPen and Skinfuse, beauty products like Body Blur and Beauty Blur, and therapeutic options including Blue Lizard and PanOxyl. Additionally, Crown Laboratories offers contract manufacturing services for various formulations including solid, liquid, and semi-liquid gels and creams. The company's commitment to dermatology drives its mission to improve the quality of life for consumers through effective skincare solutions.

GC Aesthetics PLC is a Dublin-based company that specializes in the development, manufacturing, and commercialization of silicone breast implants and related products for women. Founded in 2015, the company offers a comprehensive range of surgical implants, tissue expanders, and silicone products designed for breast augmentation, aesthetic enhancement, and reconstructive purposes. Additionally, GC Aesthetics provides innovative solutions for scar management and a variety of patient support products to facilitate informed decision-making regarding surgery. With over 30 years of industry expertise, the company is committed to empowering women on their body transformation journeys and prioritizes innovation in its product offerings. GC Aesthetics serves both surgeons and patients in Ireland and across international markets, with manufacturing facilities located in Scotland, England, and France.

Sonoma Pharmaceuticals, Inc. is a specialty pharmaceutical company based in Woodstock, Georgia, focused on developing and producing stabilized hypochlorous acid (HOCl) products for a range of applications, including wound care, dermatology, animal health, eye care, and oral care. With over 100 products commercialized in 33 countries, Sonoma addresses unmet medical needs through its innovative therapies aimed at chronic skin conditions. Key offerings include Epicyn, an antimicrobial facial cleanser; Levicyn, a prescription product for dermatoses; Celacyn gel for scar management; and SebuDerm for seborrheic dermatitis. Additionally, the company provides Microcyn, which targets various pathogens to promote wound healing, and Acuicyn, designed for eye care. Sonoma Pharmaceuticals was formerly known as Oculus Innovative Sciences, Inc. and has been incorporated since 1999. Its commitment to improving patient care and reducing healthcare costs is reflected in its diverse product portfolio that caters to both prescription and non-prescription needs.

Colorescience, Inc. is a Carlsbad, California-based company that specializes in producing and selling mineral-based cosmetics and sunscreen products. Founded in 2000, Colorescience offers a range of products including treatment solutions for pigmentation, redness, dark circles, and signs of aging, as well as products designed for sensitive, oily, and dry skin. Its offerings include UV protectors, primers, foundations, and enhancers, all formulated with high-quality, dermatologist-recommended ingredients such as minerals, antioxidants, and botanicals. The company differentiates itself in the luxury aesthetic makeup market by emphasizing efficacy, convenience, and simplicity of use. Colorescience distributes its products through a network of licensed physicians, luxury spas, retailers, and online platforms, with a commitment to addressing skin health and reducing the risk of skin cancer.

GC Aesthetics PLC is a Dublin-based company that specializes in the development, manufacturing, and commercialization of silicone breast implants and related products for women. Founded in 2015, the company offers a comprehensive range of surgical implants, tissue expanders, and silicone products designed for breast augmentation, aesthetic enhancement, and reconstructive purposes. Additionally, GC Aesthetics provides innovative solutions for scar management and a variety of patient support products to facilitate informed decision-making regarding surgery. With over 30 years of industry expertise, the company is committed to empowering women on their body transformation journeys and prioritizes innovation in its product offerings. GC Aesthetics serves both surgeons and patients in Ireland and across international markets, with manufacturing facilities located in Scotland, England, and France.

SI-BONE, Inc. is a medical device company based in Santa Clara, California, that specializes in the development and commercialization of implantable devices for surgical treatment of sacropelvic anatomy. Founded in 2008, the company offers a range of patented titanium implants, including the iFuse system, which is designed for the minimally invasive fusion of the sacroiliac joint to alleviate dysfunction that leads to lower back pain. The iFuse implant procedure is noted for its reduced invasiveness and efficiency compared to traditional open fusion methods. In addition to the iFuse system, SI-BONE develops other products such as iFuse-3D, iFuse-TORQ, and iFuse Bedrock Granite, which address various conditions related to sacroiliac joint dysfunction, spinal deformity, and pelvic trauma. The company operates both in the United States and internationally.

Kareo is a leading cloud-based clinical and business management platform tailored for independent medical practices. It offers an integrated suite of tools that addresses various administrative challenges faced by these practices, including electronic health records, practice management, billing, marketing, and patient engagement software. The platform also features third-party applications and services through the Kareo Marketplace, enhancing the delivery of care. Serving over 50,000 providers nationwide, Kareo aims to increase the efficiency and profitability of independent practices while ensuring high-quality patient care. The company has received notable industry recognition, including awards for its integrated EHR, practice management, and medical billing solutions. With multiple offices across the United States, Kareo is dedicated to supporting independent practices in navigating the complexities of the healthcare landscape.

SI-BONE, Inc. is a medical device company based in Santa Clara, California, that specializes in the development and commercialization of implantable devices for surgical treatment of sacropelvic anatomy. Founded in 2008, the company offers a range of patented titanium implants, including the iFuse system, which is designed for the minimally invasive fusion of the sacroiliac joint to alleviate dysfunction that leads to lower back pain. The iFuse implant procedure is noted for its reduced invasiveness and efficiency compared to traditional open fusion methods. In addition to the iFuse system, SI-BONE develops other products such as iFuse-3D, iFuse-TORQ, and iFuse Bedrock Granite, which address various conditions related to sacroiliac joint dysfunction, spinal deformity, and pelvic trauma. The company operates both in the United States and internationally.

Pure Life Renal, LLC is a healthcare company specializing in kidney dialysis services for patients with end-stage renal disease. Established in 2013 and headquartered in Hollywood, Florida, the company offers a comprehensive range of treatment options, including in-center hemodialysis, home hemodialysis, and peritoneal dialysis. Pure Life Renal focuses on partnering with nephrologists to enhance their ability to manage patient care effectively, providing them with the necessary business and operational support. This partnership model allows nephrologists greater autonomy in their practice while ensuring that patients receive high-quality, well-managed renal care. Pure Life Renal is committed to developing and managing dialysis clinics to meet the growing needs of patients and healthcare providers.

SI-BONE, Inc. is a medical device company based in Santa Clara, California, that specializes in the development and commercialization of implantable devices for surgical treatment of sacropelvic anatomy. Founded in 2008, the company offers a range of patented titanium implants, including the iFuse system, which is designed for the minimally invasive fusion of the sacroiliac joint to alleviate dysfunction that leads to lower back pain. The iFuse implant procedure is noted for its reduced invasiveness and efficiency compared to traditional open fusion methods. In addition to the iFuse system, SI-BONE develops other products such as iFuse-3D, iFuse-TORQ, and iFuse Bedrock Granite, which address various conditions related to sacroiliac joint dysfunction, spinal deformity, and pelvic trauma. The company operates both in the United States and internationally.

EPIRUS is focusing on the central development of a broad pipeline of biosimilar monoclonal antibodies and therapeutic proteins, optimized for use within the SCALE™ disposable manufacturing system, and designed to be deployed in an "In Market, For Market" ™ manufacturing configuration.

GC Aesthetics PLC is a Dublin-based company that specializes in the development, manufacturing, and commercialization of silicone breast implants and related products for women. Founded in 2015, the company offers a comprehensive range of surgical implants, tissue expanders, and silicone products designed for breast augmentation, aesthetic enhancement, and reconstructive purposes. Additionally, GC Aesthetics provides innovative solutions for scar management and a variety of patient support products to facilitate informed decision-making regarding surgery. With over 30 years of industry expertise, the company is committed to empowering women on their body transformation journeys and prioritizes innovation in its product offerings. GC Aesthetics serves both surgeons and patients in Ireland and across international markets, with manufacturing facilities located in Scotland, England, and France.

Mindbody is a wellness experience platform that connects users to fitness, beauty, and integrative health services. Fitness studios, salons, spas, and integrative health centers—use Mindbody's integrated software and payments platform to run, market, and grow their businesses. Consumers use Mindbody to find, engage, and transact with wellness providers in their local communities and around the world. Mindbody helps people lead healthier, happier lives by connecting the world to wellness. It was founded in 2001 and headquartered in San Luis Obispo, California.

Colorescience, Inc. is a Carlsbad, California-based company that specializes in producing and selling mineral-based cosmetics and sunscreen products. Founded in 2000, Colorescience offers a range of products including treatment solutions for pigmentation, redness, dark circles, and signs of aging, as well as products designed for sensitive, oily, and dry skin. Its offerings include UV protectors, primers, foundations, and enhancers, all formulated with high-quality, dermatologist-recommended ingredients such as minerals, antioxidants, and botanicals. The company differentiates itself in the luxury aesthetic makeup market by emphasizing efficacy, convenience, and simplicity of use. Colorescience distributes its products through a network of licensed physicians, luxury spas, retailers, and online platforms, with a commitment to addressing skin health and reducing the risk of skin cancer.

Glaukos Corporation is an ophthalmic medical technology company dedicated to developing innovative products and procedures aimed at transforming the treatment of glaucoma, a major cause of blindness worldwide. The company has pioneered Micro-Invasive Glaucoma Surgery (MIGS) to enhance traditional glaucoma management approaches. Its flagship product, the iStent, was introduced in the United States in 2012 and is designed as a micro-bypass stent that can be inserted during cataract surgery to lower intraocular pressure in adults with mild-to-moderate open-angle glaucoma. Glaukos is also advancing its product pipeline with the iStent SA, a two-stent system that utilizes a unique auto-injection inserter for standalone procedures. Founded in 1998 and headquartered in San Clemente, California, Glaukos aims to build a comprehensive portfolio of injectable micro-scale therapies to address various glaucoma disease states and progression.

EPIRUS is focusing on the central development of a broad pipeline of biosimilar monoclonal antibodies and therapeutic proteins, optimized for use within the SCALE™ disposable manufacturing system, and designed to be deployed in an "In Market, For Market" ™ manufacturing configuration.

EPIRUS is focusing on the central development of a broad pipeline of biosimilar monoclonal antibodies and therapeutic proteins, optimized for use within the SCALE™ disposable manufacturing system, and designed to be deployed in an "In Market, For Market" ™ manufacturing configuration.

Pulmonx Corporation is a medical technology company specializing in minimally invasive solutions for the diagnosis and treatment of chronic obstructive pulmonary disease (COPD), particularly severe emphysema. Its primary offerings include the Zephyr Endobronchial Valve, designed for patients with hyperinflation due to emphysema, as well as the Chartis Pulmonary Assessment System, which assesses collateral ventilation, and the StratX Lung Analysis Platform, a cloud-based service that analyzes computed tomography data to identify suitable treatment areas. Pulmonx aims to improve the quality of life for patients who remain symptomatic despite medical management and may not be candidates for surgical interventions. The company has received FDA pre-market approval for the Zephyr Valve and has established a global presence, serving markets in the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. Founded in 1995 and headquartered in Redwood City, California, Pulmonx has become a leader in interventional procedures for COPD, supported by extensive clinical evidence demonstrating the effectiveness of its technologies.

Pivot Medical is a privately held medical device company specializing in the development and marketing of innovative technologies within the orthopedic sector. The company focuses on creating minimally invasive hip-restoration systems aimed at enhancing surgical access and reducing recovery times for patients. Its product offerings include hip-replacement devices and arthroscopic surgery techniques, catering to individuals seeking effective and less invasive treatment options for orthopedic conditions. With a commitment to advancing medical solutions, Pivot Medical addresses the needs of active individuals looking for efficient and effective healthcare alternatives.

SI-BONE, Inc. is a medical device company based in Santa Clara, California, that specializes in the development and commercialization of implantable devices for surgical treatment of sacropelvic anatomy. Founded in 2008, the company offers a range of patented titanium implants, including the iFuse system, which is designed for the minimally invasive fusion of the sacroiliac joint to alleviate dysfunction that leads to lower back pain. The iFuse implant procedure is noted for its reduced invasiveness and efficiency compared to traditional open fusion methods. In addition to the iFuse system, SI-BONE develops other products such as iFuse-3D, iFuse-TORQ, and iFuse Bedrock Granite, which address various conditions related to sacroiliac joint dysfunction, spinal deformity, and pelvic trauma. The company operates both in the United States and internationally.

Glaukos Corporation is an ophthalmic medical technology company dedicated to developing innovative products and procedures aimed at transforming the treatment of glaucoma, a major cause of blindness worldwide. The company has pioneered Micro-Invasive Glaucoma Surgery (MIGS) to enhance traditional glaucoma management approaches. Its flagship product, the iStent, was introduced in the United States in 2012 and is designed as a micro-bypass stent that can be inserted during cataract surgery to lower intraocular pressure in adults with mild-to-moderate open-angle glaucoma. Glaukos is also advancing its product pipeline with the iStent SA, a two-stent system that utilizes a unique auto-injection inserter for standalone procedures. Founded in 1998 and headquartered in San Clemente, California, Glaukos aims to build a comprehensive portfolio of injectable micro-scale therapies to address various glaucoma disease states and progression.

GC Aesthetics PLC is a Dublin-based company that specializes in the development, manufacturing, and commercialization of silicone breast implants and related products for women. Founded in 2015, the company offers a comprehensive range of surgical implants, tissue expanders, and silicone products designed for breast augmentation, aesthetic enhancement, and reconstructive purposes. Additionally, GC Aesthetics provides innovative solutions for scar management and a variety of patient support products to facilitate informed decision-making regarding surgery. With over 30 years of industry expertise, the company is committed to empowering women on their body transformation journeys and prioritizes innovation in its product offerings. GC Aesthetics serves both surgeons and patients in Ireland and across international markets, with manufacturing facilities located in Scotland, England, and France.

Tobira Therapeutics, Inc. is a biotechnology company based in Princeton, New Jersey, focused on the research, development, and commercialization of antiviral compounds aimed at addressing life-threatening infectious diseases. Founded in 2006, the company specializes in developing TBR-652 and TBR-220 antagonists specifically for the treatment of HIV/AIDS and hepatitis, along with other related infectious conditions. Through its innovative approach, Tobira Therapeutics seeks to provide effective therapies for patients suffering from these serious health challenges.

Avantis Medical Systems, Inc. is a medical device company based in Sunnyvale, California, focused on developing and manufacturing catheter-based endoscopic devices. The company aims to enhance the detection and treatment of cancers and other abnormalities within the gastrointestinal (GI) tract. Leveraging decades of experience in the medical device industry, Avantis is creating innovative solutions that integrate advanced technologies, such as micro-chips and reinforced catheters. Their offerings are designed to provide safe, effective, and cost-efficient healthcare services, ultimately enhancing patient outcomes and recovery times.

Pulmonx Corporation is a medical technology company specializing in minimally invasive solutions for the diagnosis and treatment of chronic obstructive pulmonary disease (COPD), particularly severe emphysema. Its primary offerings include the Zephyr Endobronchial Valve, designed for patients with hyperinflation due to emphysema, as well as the Chartis Pulmonary Assessment System, which assesses collateral ventilation, and the StratX Lung Analysis Platform, a cloud-based service that analyzes computed tomography data to identify suitable treatment areas. Pulmonx aims to improve the quality of life for patients who remain symptomatic despite medical management and may not be candidates for surgical interventions. The company has received FDA pre-market approval for the Zephyr Valve and has established a global presence, serving markets in the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. Founded in 1995 and headquartered in Redwood City, California, Pulmonx has become a leader in interventional procedures for COPD, supported by extensive clinical evidence demonstrating the effectiveness of its technologies.

moksha8 Pharmaceuticals, Inc. is a prominent pharmaceutical company based in Berwyn, Pennsylvania, focused on licensing, marketing, and distributing therapeutics in Brazil and Mexico. Established in 2006, the company provides a range of treatments for various medical conditions, including central nervous system disorders, oncology, cardiology, rheumatology, endocrinology, and respiratory issues. Moksha8 has formed strategic alliances with notable partners such as Biopas Laboratories, Roche, Pfizer, BioCryst, and Watson, enhancing its presence and capabilities in the Latin American market.

Somaxon Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing proprietary prescription therapeutics for significant medical conditions with unmet needs and high levels of patient dissatisfaction. The company primarily targets diseases and disorders in the central nervous system therapeutic area. Currently, Somaxon promotes Silenor, the first and only nonscheduled prescription medication approved in the United States for the treatment of sleep maintenance insomnia. In addition to its focus on insomnia, Somaxon has been involved in developing products for other conditions, including middle ear infections, head lice, and cough and cold. The company's efforts are directed toward in-licensing, developing, and marketing both proprietary products and late-stage candidates to address various health challenges.

NovoStent Corporation, a medical device company that has developed a novel "anchored" helical stent technology to provide a wide range of vascular therapies.

Mako Surgical is a medical device company based in Florida, specializing in advanced robotic arm solutions and orthopedic implants for minimally invasive procedures, particularly in knee and hip surgeries. The company’s flagship offering, MAKOplasty, is a restorative surgical solution designed to assist orthopedic surgeons in treating early to mid-stage osteoarthritic conditions in patients. Mako Surgical's robotic arm interactive orthopedic system (RIO) features a tactile robotic arm and an integrated bone cutting instrument, providing pre-operative and intra-operative guidance to enhance surgical precision. This technology facilitates tissue-sparing bone removal and accurate implant insertion and alignment, ultimately improving patient outcomes. Founded in 2004, Mako Surgical has gained recognition in the medical technology field, having been named the fastest growing technology company by Deloitte and receiving multiple awards for customer excellence and innovation.

Glaukos Corporation is an ophthalmic medical technology company dedicated to developing innovative products and procedures aimed at transforming the treatment of glaucoma, a major cause of blindness worldwide. The company has pioneered Micro-Invasive Glaucoma Surgery (MIGS) to enhance traditional glaucoma management approaches. Its flagship product, the iStent, was introduced in the United States in 2012 and is designed as a micro-bypass stent that can be inserted during cataract surgery to lower intraocular pressure in adults with mild-to-moderate open-angle glaucoma. Glaukos is also advancing its product pipeline with the iStent SA, a two-stent system that utilizes a unique auto-injection inserter for standalone procedures. Founded in 1998 and headquartered in San Clemente, California, Glaukos aims to build a comprehensive portfolio of injectable micro-scale therapies to address various glaucoma disease states and progression.

Pivot Medical is a privately held medical device company specializing in the development and marketing of innovative technologies within the orthopedic sector. The company focuses on creating minimally invasive hip-restoration systems aimed at enhancing surgical access and reducing recovery times for patients. Its product offerings include hip-replacement devices and arthroscopic surgery techniques, catering to individuals seeking effective and less invasive treatment options for orthopedic conditions. With a commitment to advancing medical solutions, Pivot Medical addresses the needs of active individuals looking for efficient and effective healthcare alternatives.

Novalar Pharmaceuticals, Inc., a pharmaceutical company, develops oral pharmaceutical products. It focuses on dental products. The company’s OraVerse product (phentolamine mesylate) reverses the effects of local anesthetic with a vasoconstrictor and accelerates the return of normal sensation and function. Novalar Pharmaceuticals, Inc. was founded in 2000 and is based in San Diego, California. As of March 22, 2011, Novalar Pharmaceuticals, Inc. operates as a subsidiary of Septodont Limited.

Sequel Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes novel and clinical-stage drug candidates for patients with cardiovascular disease. The company was founded in 2007 and is based in San Diego, California.

Novalar Pharmaceuticals, Inc., a pharmaceutical company, develops oral pharmaceutical products. It focuses on dental products. The company’s OraVerse product (phentolamine mesylate) reverses the effects of local anesthetic with a vasoconstrictor and accelerates the return of normal sensation and function. Novalar Pharmaceuticals, Inc. was founded in 2000 and is based in San Diego, California. As of March 22, 2011, Novalar Pharmaceuticals, Inc. operates as a subsidiary of Septodont Limited.

KFx Medical specializes in the development and manufacturing of advanced soft tissue fixation implants specifically designed for orthopedic sports medicine. The company creates innovative products that facilitate tissue fixation, allowing for direct placement into bone, with or without sutures. These implants are utilized in various orthopedic surgical procedures, enabling surgeons to effectively reattach tissue in areas such as the shoulder, knee, foot, and ankle. KFx Medical collaborates with leading orthopedic surgeons to refine its technology and enhance surgical outcomes for patients.

Tobira Therapeutics, Inc. is a biotechnology company based in Princeton, New Jersey, focused on the research, development, and commercialization of antiviral compounds aimed at addressing life-threatening infectious diseases. Founded in 2006, the company specializes in developing TBR-652 and TBR-220 antagonists specifically for the treatment of HIV/AIDS and hepatitis, along with other related infectious conditions. Through its innovative approach, Tobira Therapeutics seeks to provide effective therapies for patients suffering from these serious health challenges.

Pulmonx Corporation is a medical technology company specializing in minimally invasive solutions for the diagnosis and treatment of chronic obstructive pulmonary disease (COPD), particularly severe emphysema. Its primary offerings include the Zephyr Endobronchial Valve, designed for patients with hyperinflation due to emphysema, as well as the Chartis Pulmonary Assessment System, which assesses collateral ventilation, and the StratX Lung Analysis Platform, a cloud-based service that analyzes computed tomography data to identify suitable treatment areas. Pulmonx aims to improve the quality of life for patients who remain symptomatic despite medical management and may not be candidates for surgical interventions. The company has received FDA pre-market approval for the Zephyr Valve and has established a global presence, serving markets in the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. Founded in 1995 and headquartered in Redwood City, California, Pulmonx has become a leader in interventional procedures for COPD, supported by extensive clinical evidence demonstrating the effectiveness of its technologies.

NovaCardia is a pharmaceutical company specializing in the development of innovative treatments for cardiovascular diseases. With a strong focus on acute cardiac care, the company is dedicated to enhancing patient outcomes through the creation and commercialization of novel small molecule drugs. Among its key projects is an oral formulation of KW-3902, aimed at treating chronic congestive heart failure. NovaCardia leverages its extensive expertise in cardiovascular drug development to address critical needs in this therapeutic area.

Transcept Pharmaceuticals, Inc. is engaged in the development of proprietary products aimed at addressing therapeutic needs in neuroscience. The company utilizes a unique delivery system that enhances drug penetration and accelerates their onset of action. Transcept is focused on creating rapid-acting formulations of several established pharmaceuticals, seeking to improve patient outcomes in various neurological conditions. The company has attracted investment from notable firms, including Montreaux Equity Partners, Peninsula Equity Partners, Vivo Ventures, New Leaf Venture Partners, Interwest Partners, and New Enterprise Associates, supporting its ongoing research and development efforts.

Pivot Medical is a privately held medical device company specializing in the development and marketing of innovative technologies within the orthopedic sector. The company focuses on creating minimally invasive hip-restoration systems aimed at enhancing surgical access and reducing recovery times for patients. Its product offerings include hip-replacement devices and arthroscopic surgery techniques, catering to individuals seeking effective and less invasive treatment options for orthopedic conditions. With a commitment to advancing medical solutions, Pivot Medical addresses the needs of active individuals looking for efficient and effective healthcare alternatives.

Avantis Medical Systems, Inc. is a medical device company based in Sunnyvale, California, focused on developing and manufacturing catheter-based endoscopic devices. The company aims to enhance the detection and treatment of cancers and other abnormalities within the gastrointestinal (GI) tract. Leveraging decades of experience in the medical device industry, Avantis is creating innovative solutions that integrate advanced technologies, such as micro-chips and reinforced catheters. Their offerings are designed to provide safe, effective, and cost-efficient healthcare services, ultimately enhancing patient outcomes and recovery times.

NovaCardia is a pharmaceutical company specializing in the development of innovative treatments for cardiovascular diseases. With a strong focus on acute cardiac care, the company is dedicated to enhancing patient outcomes through the creation and commercialization of novel small molecule drugs. Among its key projects is an oral formulation of KW-3902, aimed at treating chronic congestive heart failure. NovaCardia leverages its extensive expertise in cardiovascular drug development to address critical needs in this therapeutic area.

SkinMedica is a company dedicated to developing, acquiring, and commercializing products aimed at improving skin appearance. It specializes in both prescription and non-prescription skincare solutions marketed primarily to physicians and medical spas. The company's notable offerings include the TNS Essential Serum® and TNS Recovery Complex®, which are designed to enhance skin quality, reduce signs of aging, and deliver various skincare benefits. SkinMedica's prescription product, VANIQA® Cream, is the only FDA-approved treatment for the reduction of unwanted facial hair in women. Additionally, SkinMedica's portfolio includes a range of aesthetic skincare products, moisturizers, sun protection, and specialized treatments for conditions such as acne and sensitive skin. The company also features Colorescience Pro, a line of dermatologist-recommended cosmetics that address specific skin concerns while providing sun protection.

Bayhill Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapeutics for autoimmune diseases. The company uses its therapeutic BHT-DNA platform to develop a pipeline of treatment candidates for autoimmune diseases. Its products in clinical pipeline include BHT-3021, which is in Phase I/II clinical trial for reducing or eliminating the immune system’s attack on the pancreas; BHT-3009, which completed its Phase II trial for the treatment of multiple sclerosis; and BHT-3034, which is in preclinical studies for the treatment of myasthenia gravis. The company was formerly known as Tolerion, Inc. and changed its name to Bayhill Therapeutics, Inc. in November 2002. Bayhill Therapeutics, Inc. was founded in 2000 and is headquartered in Palo Alto, California.

Aryx Therapeutics is a biopharmaceutical company that specializes in the development of innovative oral therapies aimed at chronic diseases. The company leverages its expertise in retrometabolic drug design to create product candidates that address and eliminate safety concerns associated with existing, commercially successful medications. By focusing on improving the safety profiles of these therapies, Aryx Therapeutics seeks to enhance patient outcomes and provide better treatment options in the pharmaceutical market. The company's commitment to advancing drug safety is supported by a strong portfolio of intellectual property.

Asthmatx is a medical device company based in Mountain View, California, founded in 2003 and now operating as a subsidiary of Boston Scientific. The company specializes in developing and commercializing therapeutic treatments for asthma. Asthmatx has created a technology that delivers controlled thermal energy to the airways of adult patients to reduce airway smooth muscle mass through a procedure known as Bronchial Thermoplasty. Their flagship product is the Alair System, an interventional medical device designed for bronchoscopic treatment of moderate to severe asthma.

NeurogesX, Inc. is a specialty pharmaceutical company based in San Mateo, California, established in 1998. Originally named Advanced Analgesics, Inc., the company focuses on developing and commercializing innovative non-opioid therapies for pain management, specifically targeting chronic peripheral neuropathic pain conditions such as postherpetic neuralgia, painful HIV-distal sensory polyneuropathy, and painful diabetic neuropathy. Its lead product, Qutenza, is an 8% capsaicin dermal patch designed to alleviate pain associated with these conditions. Additionally, NeurogesX is working on NGX-1998, a non-patch liquid formulation of synthetic capsaicin, as well as an opioid analgesic for managing pain due to other chronic conditions, including cancer pain.

KFx Medical specializes in the development and manufacturing of advanced soft tissue fixation implants specifically designed for orthopedic sports medicine. The company creates innovative products that facilitate tissue fixation, allowing for direct placement into bone, with or without sutures. These implants are utilized in various orthopedic surgical procedures, enabling surgeons to effectively reattach tissue in areas such as the shoulder, knee, foot, and ankle. KFx Medical collaborates with leading orthopedic surgeons to refine its technology and enhance surgical outcomes for patients.

Cerexa is a biopharmaceutical company dedicated to developing innovative anti-infective therapies aimed at addressing serious and life-threatening infections, particularly those caused by antibiotic-resistant bacteria. The company’s primary product is Ceftaroline Acetate, an injectable cephalosporin designed to treat bacterial infections stemming from both gram-positive and gram-negative pathogens. Through its focus on novel therapeutic solutions, Cerexa addresses a critical need in the healthcare landscape for effective treatments against challenging infections.

Verus Pharmaceuticals is a pediatric-oriented company that identifies, develops, and delivers solutions to address the unmet medical needs of children and those who care for them. It offers treatment of asthma, allergies, and related diseases and conditions. The company also offers Twinject, an epinephrine auto-injector for anaphylaxis. Verus Pharmaceuticals is based in San Diego, California.

Somaxon Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing proprietary prescription therapeutics for significant medical conditions with unmet needs and high levels of patient dissatisfaction. The company primarily targets diseases and disorders in the central nervous system therapeutic area. Currently, Somaxon promotes Silenor, the first and only nonscheduled prescription medication approved in the United States for the treatment of sleep maintenance insomnia. In addition to its focus on insomnia, Somaxon has been involved in developing products for other conditions, including middle ear infections, head lice, and cough and cold. The company's efforts are directed toward in-licensing, developing, and marketing both proprietary products and late-stage candidates to address various health challenges.

Bayhill Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapeutics for autoimmune diseases. The company uses its therapeutic BHT-DNA platform to develop a pipeline of treatment candidates for autoimmune diseases. Its products in clinical pipeline include BHT-3021, which is in Phase I/II clinical trial for reducing or eliminating the immune system’s attack on the pancreas; BHT-3009, which completed its Phase II trial for the treatment of multiple sclerosis; and BHT-3034, which is in preclinical studies for the treatment of myasthenia gravis. The company was formerly known as Tolerion, Inc. and changed its name to Bayhill Therapeutics, Inc. in November 2002. Bayhill Therapeutics, Inc. was founded in 2000 and is headquartered in Palo Alto, California.

NovaCardia is a pharmaceutical company specializing in the development of innovative treatments for cardiovascular diseases. With a strong focus on acute cardiac care, the company is dedicated to enhancing patient outcomes through the creation and commercialization of novel small molecule drugs. Among its key projects is an oral formulation of KW-3902, aimed at treating chronic congestive heart failure. NovaCardia leverages its extensive expertise in cardiovascular drug development to address critical needs in this therapeutic area.

SkinMedica is a company dedicated to developing, acquiring, and commercializing products aimed at improving skin appearance. It specializes in both prescription and non-prescription skincare solutions marketed primarily to physicians and medical spas. The company's notable offerings include the TNS Essential Serum® and TNS Recovery Complex®, which are designed to enhance skin quality, reduce signs of aging, and deliver various skincare benefits. SkinMedica's prescription product, VANIQA® Cream, is the only FDA-approved treatment for the reduction of unwanted facial hair in women. Additionally, SkinMedica's portfolio includes a range of aesthetic skincare products, moisturizers, sun protection, and specialized treatments for conditions such as acne and sensitive skin. The company also features Colorescience Pro, a line of dermatologist-recommended cosmetics that address specific skin concerns while providing sun protection.

Orexigen Therapeutics, Inc. is a biopharmaceutical company based in La Jolla, California, specializing in the development of pharmaceutical products aimed at treating obesity. Founded in 2002, the company has advanced its lead product candidate, Contrave, through Phase III clinical trials. Contrave is a combination of bupropion, an antidepressant and smoking cessation aid, and naltrexone, a medication for alcohol and opioid addiction, formulated for sustained release. Additionally, Orexigen is developing Empatic, which has completed Phase II clinical trials; this product combines bupropion with zonisamide, a drug used in the treatment of partial seizures. Orexigen focuses on leveraging existing drugs to create synergistic effects, particularly in the neuroscience space, with a clear emphasis on addressing obesity through innovative therapeutic solutions.

Novalar Pharmaceuticals, Inc., a pharmaceutical company, develops oral pharmaceutical products. It focuses on dental products. The company’s OraVerse product (phentolamine mesylate) reverses the effects of local anesthetic with a vasoconstrictor and accelerates the return of normal sensation and function. Novalar Pharmaceuticals, Inc. was founded in 2000 and is based in San Diego, California. As of March 22, 2011, Novalar Pharmaceuticals, Inc. operates as a subsidiary of Septodont Limited.

Avera Pharmaceuticals is a specialty pharmaceutical company that acquires, develops, and commercializes pharmaceutical compounds. The company develops gantacurium, a neuromuscular blocking agent for rapid and routine endotracheal intubation and skeletal muscle relaxation during surgery; AV810 for the treatment of overactive bladder and irritable bowel syndrome; and AV965 to treat cognitive impairment associated with schizophrenia and Alzheimer’s dementia. The company was founded in 2002 and is headquartered in San Diego, California.

SkinMedica is a company dedicated to developing, acquiring, and commercializing products aimed at improving skin appearance. It specializes in both prescription and non-prescription skincare solutions marketed primarily to physicians and medical spas. The company's notable offerings include the TNS Essential Serum® and TNS Recovery Complex®, which are designed to enhance skin quality, reduce signs of aging, and deliver various skincare benefits. SkinMedica's prescription product, VANIQA® Cream, is the only FDA-approved treatment for the reduction of unwanted facial hair in women. Additionally, SkinMedica's portfolio includes a range of aesthetic skincare products, moisturizers, sun protection, and specialized treatments for conditions such as acne and sensitive skin. The company also features Colorescience Pro, a line of dermatologist-recommended cosmetics that address specific skin concerns while providing sun protection.

Somaxon Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing proprietary prescription therapeutics for significant medical conditions with unmet needs and high levels of patient dissatisfaction. The company primarily targets diseases and disorders in the central nervous system therapeutic area. Currently, Somaxon promotes Silenor, the first and only nonscheduled prescription medication approved in the United States for the treatment of sleep maintenance insomnia. In addition to its focus on insomnia, Somaxon has been involved in developing products for other conditions, including middle ear infections, head lice, and cough and cold. The company's efforts are directed toward in-licensing, developing, and marketing both proprietary products and late-stage candidates to address various health challenges.

Aryx Therapeutics is a biopharmaceutical company that specializes in the development of innovative oral therapies aimed at chronic diseases. The company leverages its expertise in retrometabolic drug design to create product candidates that address and eliminate safety concerns associated with existing, commercially successful medications. By focusing on improving the safety profiles of these therapies, Aryx Therapeutics seeks to enhance patient outcomes and provide better treatment options in the pharmaceutical market. The company's commitment to advancing drug safety is supported by a strong portfolio of intellectual property.

NeurogesX, Inc. is a specialty pharmaceutical company based in San Mateo, California, established in 1998. Originally named Advanced Analgesics, Inc., the company focuses on developing and commercializing innovative non-opioid therapies for pain management, specifically targeting chronic peripheral neuropathic pain conditions such as postherpetic neuralgia, painful HIV-distal sensory polyneuropathy, and painful diabetic neuropathy. Its lead product, Qutenza, is an 8% capsaicin dermal patch designed to alleviate pain associated with these conditions. Additionally, NeurogesX is working on NGX-1998, a non-patch liquid formulation of synthetic capsaicin, as well as an opioid analgesic for managing pain due to other chronic conditions, including cancer pain.

Peninsula Pharmaceuticals, Inc. is a specialty pharmaceutical company dedicated to the licensing, development, and commercialization of anti-infective therapies aimed at treating life-threatening infections in North America and Europe. The company's primary focus is on its lead product candidate, doripenem, a broad-spectrum antibiotic classified as a carbapenem. Currently, Peninsula is conducting six Phase III clinical trials for doripenem, which has also received Fast Track designation from the U.S. Food and Drug Administration for the treatment of nosocomial pneumonia, including ventilator-associated pneumonia. The company was acquired by Johnson & Johnson, a global leader in healthcare products and services. As a privately held biopharmaceutical entity, Peninsula Pharmaceuticals concentrates on advancing antibiotics to address critical infection-related health challenges.

Pulmonx Corporation is a medical technology company specializing in minimally invasive solutions for the diagnosis and treatment of chronic obstructive pulmonary disease (COPD), particularly severe emphysema. Its primary offerings include the Zephyr Endobronchial Valve, designed for patients with hyperinflation due to emphysema, as well as the Chartis Pulmonary Assessment System, which assesses collateral ventilation, and the StratX Lung Analysis Platform, a cloud-based service that analyzes computed tomography data to identify suitable treatment areas. Pulmonx aims to improve the quality of life for patients who remain symptomatic despite medical management and may not be candidates for surgical interventions. The company has received FDA pre-market approval for the Zephyr Valve and has established a global presence, serving markets in the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. Founded in 1995 and headquartered in Redwood City, California, Pulmonx has become a leader in interventional procedures for COPD, supported by extensive clinical evidence demonstrating the effectiveness of its technologies.

Marketwired is a social communications company that specializes in press release distribution and communication workflow services. Founded in 1983 and headquartered in Toronto, Ontario, it offers a comprehensive suite of solutions that includes social media monitoring, analytics, and a marketing communications platform for content creation, optimization, distribution, and measurement. Marketwired serves a diverse clientele, ranging from Fortune 500 companies to start-ups, and plays a vital role in influencing public discourse across newsrooms, corporate environments, and social networks. Its services are designed to help clients manage public relations and investor relations effectively, facilitating engagement and impacting consumer behavior.

Peninsula Pharmaceuticals, Inc. is a specialty pharmaceutical company dedicated to the licensing, development, and commercialization of anti-infective therapies aimed at treating life-threatening infections in North America and Europe. The company's primary focus is on its lead product candidate, doripenem, a broad-spectrum antibiotic classified as a carbapenem. Currently, Peninsula is conducting six Phase III clinical trials for doripenem, which has also received Fast Track designation from the U.S. Food and Drug Administration for the treatment of nosocomial pneumonia, including ventilator-associated pneumonia. The company was acquired by Johnson & Johnson, a global leader in healthcare products and services. As a privately held biopharmaceutical entity, Peninsula Pharmaceuticals concentrates on advancing antibiotics to address critical infection-related health challenges.

PartnerGate specializes in domain management, development and programming.

NeurogesX, Inc. is a specialty pharmaceutical company based in San Mateo, California, established in 1998. Originally named Advanced Analgesics, Inc., the company focuses on developing and commercializing innovative non-opioid therapies for pain management, specifically targeting chronic peripheral neuropathic pain conditions such as postherpetic neuralgia, painful HIV-distal sensory polyneuropathy, and painful diabetic neuropathy. Its lead product, Qutenza, is an 8% capsaicin dermal patch designed to alleviate pain associated with these conditions. Additionally, NeurogesX is working on NGX-1998, a non-patch liquid formulation of synthetic capsaicin, as well as an opioid analgesic for managing pain due to other chronic conditions, including cancer pain.

Marketwired is a social communications company that specializes in press release distribution and communication workflow services. Founded in 1983 and headquartered in Toronto, Ontario, it offers a comprehensive suite of solutions that includes social media monitoring, analytics, and a marketing communications platform for content creation, optimization, distribution, and measurement. Marketwired serves a diverse clientele, ranging from Fortune 500 companies to start-ups, and plays a vital role in influencing public discourse across newsrooms, corporate environments, and social networks. Its services are designed to help clients manage public relations and investor relations effectively, facilitating engagement and impacting consumer behavior.

NeurogesX, Inc. is a specialty pharmaceutical company based in San Mateo, California, established in 1998. Originally named Advanced Analgesics, Inc., the company focuses on developing and commercializing innovative non-opioid therapies for pain management, specifically targeting chronic peripheral neuropathic pain conditions such as postherpetic neuralgia, painful HIV-distal sensory polyneuropathy, and painful diabetic neuropathy. Its lead product, Qutenza, is an 8% capsaicin dermal patch designed to alleviate pain associated with these conditions. Additionally, NeurogesX is working on NGX-1998, a non-patch liquid formulation of synthetic capsaicin, as well as an opioid analgesic for managing pain due to other chronic conditions, including cancer pain.

StorageWay, Inc. provides storage utility services. Its services are offered by Internet infrastructure providers in Santa Clara, New York, Atlanta, Chicago, Washington DC, and Dallas; and Toronto, Canada.

Internet Generation Storage

PartnerGate specializes in domain management, development and programming.

Cephren – the master builder of the great pyramids. He changed the way the world was built. With the help of their customers, they will too! Welcome to Cephren, the premier business-to-business online workplace for the global construction industry. Cephren unites all participants in the industry with the first end-to-end, Web-based framework of e-commerce and collaboration services. Whether you're an owner or developer, architect or engineer, general contractor or subcontractor, distributor or manufacturer, Cephren's online workplace addresses your needs throughout the design-to-build process, enabling you to do business smarter, faster and more cost effectively.

Marketwired is a social communications company that specializes in press release distribution and communication workflow services. Founded in 1983 and headquartered in Toronto, Ontario, it offers a comprehensive suite of solutions that includes social media monitoring, analytics, and a marketing communications platform for content creation, optimization, distribution, and measurement. Marketwired serves a diverse clientele, ranging from Fortune 500 companies to start-ups, and plays a vital role in influencing public discourse across newsrooms, corporate environments, and social networks. Its services are designed to help clients manage public relations and investor relations effectively, facilitating engagement and impacting consumer behavior.